<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:arxiv="http://arxiv.org/schemas/atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title>q-bio.MN updates on arXiv.org</title>
    <link>http://rss.arxiv.org/rss/q-bio.MN</link>
    <description>q-bio.MN updates on the arXiv.org e-print archive.</description>
    <atom:link href="http://rss.arxiv.org/rss/q-bio.MN" rel="self" type="application/rss+xml"/>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <language>en-us</language>
    <lastBuildDate>Fri, 05 Dec 2025 05:04:06 +0000</lastBuildDate>
    <managingEditor>rss-help@arxiv.org</managingEditor>
    <pubDate>Fri, 05 Dec 2025 00:00:00 -0500</pubDate>
    <skipDays>
      <day>Saturday</day>
      <day>Sunday</day>
    </skipDays>
    <item>
      <title>A Systemic Pathological Network Model and Combinatorial Intervention Strategies for Alzheimer's Disease</title>
      <link>https://arxiv.org/abs/2512.04937</link>
      <description>arXiv:2512.04937v1 Announce Type: new 
Abstract: Alzheimer's disease (AD) persists as a paramount challenge in neurological research, characterized by the pathological hallmarks of amyloid-$\beta$ (A$\beta$) plaques and neurofibrillary tangles composed of hyperphosphorylated tau. This review synthesizes the evolving understanding of AD pathogenesis, moving beyond the linear amyloid cascade hypothesis to conceptualize the disease as a cross-talk of intricately interacting pathologies, encompassing A$\beta$, tau, and neuroinflammation as the foundation of phase-adapted pathological network model. This evolving pathophysiological understanding parallels a transformation in diagnostic paradigms, where biomarker-based strategies such as the AT(N) framework enable early disease detection during preclinical or prodromal stages. Within this new landscape, while anti-A$\beta$ monoclonal antibodies (e.g., lecanemab, donanemab), represent a breakthrough as the first disease-modifying therapies, their modest efficacy underscores the limitation of single-target approaches. Therefore, I explore the compelling rationale for combination therapies that simultaneously target A$\beta$ pathology, aberrant tau, and neuroinflammation. Looking forward, I emphasize emerging technological platforms such as gene editing and biophysical neuromodulation in advancing precision medicine. Ultimately, the integration of early biomarker detection, multi-target therapeutic strategies, and AI-driven patient stratification charts a promising roadmap toward fundamentally altering the trajectory of AD. The future of AD management will be defined by preemptive, biomarker-guided, and personalized combination interventions.
Keywords: Alzheimer's disease, amyloid-$\beta$, tau pathology, neuroinflammation, combination therapy, multi-target therapy, precision medicine, biomarkers</description>
      <guid isPermaLink="false">oai:arXiv.org:2512.04937v1</guid>
      <category>q-bio.MN</category>
      <pubDate>Fri, 05 Dec 2025 00:00:00 -0500</pubDate>
      <arxiv:announce_type>new</arxiv:announce_type>
      <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
      <dc:creator>She Xutong</dc:creator>
    </item>
  </channel>
</rss>
